(S)-6-methyl-7-(2H-tetrahydropyran-2-yloxy)-heptan-2-one | 220775-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (S)-6-methyl-7-(2H-tetrahydropyran-2-yloxy)-heptan-2-one
• 英文别名: (6S)-6-Methyl-7-(tetrahydro-2H-pyran-2-yloxy)-heptan-2-one；(S)-6-Methyl-7-[(RS)-(3,4,5,6-tetrahydro-2H-pyran-2-yl)oxy]heptan-2-one；(2S)-2-methyl-6-oxo-heptane-1-(tetrahydropyran-2-yloxy)；(6S)-6-Methyl-7-(tetrahydro-2H-pyran-2-yloxy)heptan-2-one；(6S)-6-methyl-7-(oxan-2-yloxy)heptan-2-one
• CAS: 220775-18-8
• 化学式: C₁₃H₂₄O₃
• 分子量: 228.332
• InChiKey: QATYWYWXGPNTNI-AMGKYWFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-6-methyl-7-(2H-tetrahydropyran-2-yloxy)-heptan-2-one 在 对甲苯磺酸 作用下， 以 乙醇 为溶剂， 反应 2.5h， 以83.9%的产率得到2-庚酮,7-羟基-6-甲基-,(S)-(9CI)
  参考文献：
  名称：

  [DE] VERFAHREN FÜR DIE HERSTELLUNG VON C1-C15-FRAGMENTEN VON EPOTHILONEN UND DEREN DERIVATEN
  [EN] METHOD FOR PRODUCING C1-C15 FRAGMENTS OF EPOTHILONES AND THE DERIVATIVES THEREOF
  [FR] PROCEDE DE FABRICATION DE FRAGMENTS C1-C15 D'EPOTHILONES ET DE LEURS DERIVES

  摘要：

  本发明描述了一种制备Epothilone及其衍生物的C1-C15片段的方法，其中将一个C1-C6片段与一个C7-C12片段连接成一个C1-C12片段，然后将其与一个C13-C15片段反应以制备C1-C15 Epothilon前体。通过已知方法，可以将得到的C1-C15 Epothilon前体转化为实际的药物。该发明还涉及相应的C1-C12片段。

  公开号：

  WO2005003071A1
• 作为产物：
  描述：

  (2S)-2-甲基-3-(四氢吡喃-2-氧基)丙烷-1-醇 在 吡啶 、 sodium periodate 、 四氧化锇 、 magnesium 作用下， 以 四氢呋喃 、 水 、 叔丁醇 为溶剂， 反应 49.5h， 生成 (S)-6-methyl-7-(2H-tetrahydropyran-2-yloxy)-heptan-2-one
  参考文献：
  名称：

  ZK-EPO的总合成和抗肿瘤活性：临床开发中的第一个完全合成的埃博霉素。

  摘要：

  DOI：

  10.1002/anie.200602785

文献信息

• EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE
  申请人：——

  公开号：US20030144523A1

  公开（公告）日：2003-07-31

  This invention relates to the new epothilone derivatives of general formula I, 1 in which substituents Y, Z R 2a , R 2b , R 3 , R 4a , R 4b , D—E, R 5 , R 6 , R 7 , R 8 and X have the meanings that are indicated in more detail in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanomas, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (psoriasis, arthritis). To avoid uncontrolled proliferation of cells and for better compatibility of medical implants, they can be applied or introduced into polymer materials. The compounds according to the invention can be used alone or to achieve additive or synergistic actions in combination with other principles and classes of substances that can be used in tumor therapy.

  本发明涉及具有通式I的新埃波替隆衍生物，其中取代基Y、Z、R2a、R2b、R3、R4a、R4b、D—E、R5、R6、R7、R8和X的含义在描述中更详细地指出。这些新化合物通过与微管蛋白的相互作用来稳定形成的微管。它们能够以阶段特异性的方式影响细胞分裂，并适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺体、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓细胞白血病。此外，它们还适用于抗血管生成治疗以及治疗慢性炎性疾病（银屑病、关节炎）。为了避免细胞的不受控制的增殖以及提高医疗植入物的相容性，它们可以应用于或引入到聚合物材料中。根据发明的化合物可以单独使用，也可以与其他可用于肿瘤治疗的原理和物质类别结合使用，以实现相加或协同作用。
• Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
  申请人：Schering, AG

  公开号：US07001916B1

  公开（公告）日：2006-02-21

  Disclosed are epothilone compounds of formula I, which are useful as pharmaceutical compounds for treating, for example, malignant tumors and chronic inflammatory diseases and are useful in anti-angiogenesis therapy.

  揭示了公式I的依托利定化合物，这些化合物可用作治疗恶性肿瘤和慢性炎症性疾病的药物化合物，并在抗血管生成治疗中有用。
• 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
  申请人：Klar Ulrich

  公开号：US20050113429A1

  公开（公告）日：2005-05-26

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2b , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

  该发明描述了通式(I)中的新6-烯基-和6-炔基-epothilone衍生物，其中R1a、R1b、R2b、R3a、R3b、R4、R5、R6、R7、A、Y、D、E、G、Y和Z具有说明中指示的含义。这些新化合物通过稳定形成的微管蛋白质与微管结合。它们能够以特定阶段的方式影响细胞分裂，因此可用于治疗与细胞生长、分裂和/或增殖需求相关的疾病或状况。因此，这些化合物适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺癌、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓性白血病。此外，它们也适用于抗血管生成治疗以及慢性炎症性疾病的治疗（如牛皮癣、关节炎）。还描述了这些化合物的使用方法和制备方法。
• 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
  申请人：Klar Ulrich

  公开号：US20060046997A1

  公开（公告）日：2006-03-02

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2a , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

  该发明描述了新的6-烯基和6-炔基-依托酮衍生物，其一般式为（I），其中R1a、R1b、R2a、R3a、R3b、R4、R5、R6、R7、A、Y、D、E、G、Y和Z的含义如描述中所示。这些新化合物通过稳定形成的微管蛋白质与微管相互作用。它们能够以特定于阶段的方式影响细胞分裂，因此可用于治疗与细胞生长、分裂和/或增殖需求相关的疾病或症状。因此，这些化合物适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺癌、乳腺癌、肺癌、头颈癌、恶性黑色素瘤、急性淋巴细胞白血病和骨髓性白血病。此外，它们也适用于抗血管生成治疗以及慢性炎症性疾病（如牛皮癣、关节炎）的治疗。该文还描述了这些化合物的使用方法和制备方法。
• Novel chiral heptyne derivates for the preparation of epothilones and processes for their preparation
  申请人：Schering Aktiengesellschaft

  公开号：EP1589011A1

  公开（公告）日：2005-10-26

  The invention relates to a new synthetic process for the production of key intermediates useful in the synthesis of epothilones or epothilone derivatives, to certain compounds used to produce these key intermediates and to a process to produce said compounds. The intermediates used are represented by formulae II and III, wherein R is selected from H, alkyl and substituded alkyl and X1 is an oxygen protecting group.

  本发明涉及一种用于合成依泼替尼或依泼替尼衍生物的关键中间体的新合成方法，以及用于生产这些关键中间体的某些化合物和生产该化合物的方法。所使用的中间体由式II和III表示，其中R选自H，烷基和取代烷基，X1是一个保护氧原子的基团。